Neurosense Therapeutics is trading 5.26% up now at $7.40 following extreme volatility after its 1-for-20 reverse stock split, effective September 14, 2026.
- The transaction reduced expected shares outstanding from 37,938,036 to approximately 1,896,902 and introduced a new CUSIP, creating a substantially smaller trading float.
- The split was implemented to address Nasdaq’s minimum-bid requirement.
- The company’s September 15 investor conference presentation provided no clearly reported new clinical or financing catalyst.